Trding , and you have a great memory , and you are right ,
Dr Pestell was accepting to the study only the patients CCR5 positive on the tumor cells ,
but now we know that this happening only in about 20% of cancer patients , about 80% of the patients are CCR5 positive in the surrounding tissue only , and they responding well to CCR5 inhibitors ..
Our very , very first patient accepted to the cancer study finally by Dr NP , received 1 or 2 injections of Leronlimab sometimes June - July of 2019 , but when her final result of tests came back , showing no CCR5 on the tumor cells but only on the surrounding tissue , Dr Pestell removed her from the study , with the objections of Dr Patterson , who already started to work with Cydy , and who stated this will be ok , and to continue Leronlimab with her ..
And since we know now that only about 20% of the cancer patients are CCR5 positive on the tumor cells , rest are positive on the surrounding tissue, but they are responding well to Leronlimab , he will have almost impossible task to enroll ever ...
So yes , with Dr Pestell knowledge on that matter only , we will never have full enrollment , in addition , as he said , starting designing protocol for this study in November of 2018 , and then June -July of 2019 he could not , as he said , come up with a safe one ..
How difficult is to design a very safe protocol for a very safe drug ..??
Really Dr Pestell ??
IMO there must be something more then that in play at the time on his part ..
All imo ..
GLTA longs ..
